56 citations
,
July 2008 in “European journal of endocrinology” This study found that a 6-month treatment with either metformin or rosiglitazone significantly improved endothelial function in young women with PCOS without any one drug being superior.
1 citations
,
June 1987 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that despite a high incidence of side effects, patients generally tolerated spironolactone while benefiting from its treatment effects for acne and hirsutism.
40 citations
,
April 2008 in “European journal of endocrinology” In this study, treatment with insulin sensitizers significantly increased adipose tissue GLUT4 mRNA expression and improved insulin resistance, menstrual patterns, and androgen profiles in PCOS patients, with rosiglitazone being more effective than metformin.
This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.
34 citations
,
June 2010 in “Archives of Disease in Childhood” This review discusses normal menstrual variations and common menstrual disorders in adolescent girls, focusing on symptoms, evaluation, and management, but does not present new clinical results.